

Preliminary Q2 2025 Financial Results

■ Revenue

- Revenue for 2Q25 recorded KRW 961.5 billion, up +9.9% YoY
- Sales of high-margin young products, including Remsima SC and Zymfentra, more than doubled YoY, driving overall revenue growth
- The sales contribution of high-margin young products rose significantly to 53% from 30% YoY, contributing to margin improvement
- With four additional product launches scheduled in 2H25, momentum for new product-led growth is expected to strengthen further
- Sales of advanced products declined YoY due to a high base from temporary supply expansion in 1H 2024, but remained stable excluding this effect
- Non-bio sales declined YoY following the transfer of Takeda's primary care rights, with limited impact on operating profit
- Sales and profit are expected to grow in tandem through continued portfolio optimization focused on high-margin young products

■ Operating Profit

- 2Q25 OP reached KRW 242.5 billion, up +234.5% YoY, with the operating margin rising sharply from 8.3% to 25.2% a year earlier
- Multiple factors that decreased the COGS ratio led to an overall improvement in OPM(COGS ratio: 2Q24 58% → 1Q25 47% → 2Q25 43%)
 - **Product Mix:** Increasing portion of high-margin young products led COGS reduction and margin improvement. Further improvement is expected as the young products contribution continues to increase
 - **Merger Effects:** Merger impact reduced, with high-cost inventory mostly depleted and amortization of sales rights concluded
 - **Manufacturing Cost:** Contract manufacturing for drug substances in 2025 was completed in Q1. Starting in Q2, all products are being manufactured in-house, with advanced products fully transitioned to the titer-improved version
 - **R&D Amortization:** Amortization of development costs for advanced products has ended (Herzuma amortization completed; Remsima to be completed by Q3 2025)

[Unit: KRW billion]										
			2Q25(P)	2Q24	YoY	1Q25	QoQ	1H25(P)	1H24	YoY
Sales			961.5	874.7	9.9%	841.9	14.2%	1,803.4	1,611.7	11.9%
Biologics			882.8	774.0	14.1%	767.6	15.0%	1,650.4	1,425.2	15.8%
Product	Advanced ¹⁾		414.8	540.6	-23.3%	420.4	-1.3%	835.2	977.8	-14.6%
	Young ²⁾		468.0	233.4	100.5%	347.2	34.8%	815.2	447.4	82.2%
Non-Biologics			78.7	100.7	-21.8%	74.3	5.9%	153.0	186.5	-18.0%
Gross Profit			544.4	367.8	48.0%	442.9	22.9%	987.3	674.5	46.4%
GPM(%)			56.6%	42.0%	14.6%p	52.6%	4.0%p	54.7%	41.9%	12.9%p
Operating Profit			242.5	72.5	234.5%	149.4	62.3%	391.9	87.9	345.8%
OPM(%)			25.2%	8.3%	16.9%p	17.7%	7.5%p	21.7%	5.5%	16.3%p

1) Advanced: Remsima, Truxima, Herzuma
2) Young: Remsima SC, Yuflyma, Vegzelma, Zymfentra, Steqeyma, etc.

The above preliminary financial results are based on the company's internal accounting data and have not been reviewed by an external auditor. They are provided for investors' convenience only and may differ from the final audited results.